^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Published date:
12/20/2023
Excerpt:
The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5). The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively...Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.
DOI:
10.1200/JCO.23.00606
Trial ID:
Source:
Title:
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
Published date:
05/25/2023
Excerpt:
cORR was 46.7% (90% CI, 30.8, 63.0), with 14 responses including 1 complete and 13 partial responses. Median DOR was 6.0 months (90% CI, 5.5, not estimable). DCR was 76.7% (n=23; 90% CI, 60.6, 88.5), and median PFS was 5.5 months (90% CI, 3.9, 8.1)….The combination of TUC and Tras was well tolerated in pts with previously treated HER2+ metastatic BTC. The observed antitumor activity supports the combination of TUC and Tras as a future chemotherapy-free treatment option for this population with historically poor outcomes.
DOI:
10.1200/JCO.2023.41.16_suppl.4007
Trial ID: